Last Updated: August 3, 2026

Litigation Details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Docket 1:22-cv-00464 Date Filed 2022-04-08
Court District Court, D. Delaware Date Terminated 2024-05-30
Cause 35:271 Patent Infringement Assigned To Jennifer L. Hall
Jury Demand None Referred To
Parties OTSUKA PHARMACEUTICAL CO., LTD.
Patents 10,525,057; 10,980,803; 11,154,553; 11,344,547; 11,400,087; 7,807,680; 8,030,313; 8,338,427; 8,399,469; 8,722,679
Attorneys A. Sasha Hoyt
Firms Wilson Sonsini Goodrich & Rosati PC
Link to Docket External link to docket
Small Molecule Drugs cited in Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Date Filed Document No. Description Snippet Link To Document
2022-04-08 External link to document
2022-04-08 144 Report and Recommendations ,469 (the “’469 patent”), 10,525,057 (the “’057 patent”), 10,980,803 (the “’803 patent”), 11,154,553…across seven patents. The seven patents are U.S. Patent Nos. 8,338,427 (the “’427 patent”), 8,399,469… (the “’553 patent”), 11,344,547 (the “’547 patent”), and 11,400,087 (the “’087 patent”). I held … patent, claims 1, 10, and 25; ’547 patent, claims 1, 7, and 16; ’087 patent, claims 1… the ’803 patent. 16 The ’803 patent is a continuation of the ’057 patent and shares External link to document
2022-04-08 222 Notice of Service Invalidity of The Cyp Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,…Invalidity of The Cyp Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,… Jonathan W. Steed Regarding Invalidity of U.S. Patent No. 8,399,469 [Highly Confidential], and Opening… 2022 30 May 2024 1:22-cv-00464 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2022-04-08 253 Notice of Service Invalidity of the CYP Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,…Invalidity of the CYP Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,… Jonathan W. Steed Regarding Invalidity of U.S. Patent No. 8,399,469; 4) Expert Report of Dr. Yaning Wang… 2022 30 May 2024 1:22-cv-00464 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.